{
    "pmid": "41375204",
    "title": "A CRISPR Powered Immobilization-Free, Amplification-Free Carbon-Nanotube Field-Effect Transistor (FET) Sensor for Influenza A Virus (IAV).",
    "abstract": "The epidemic of infectious diseases, such as influenza A, has imposed a severe health burden on the population. Early detection, diagnosis, reporting, isolation, and treatment are crucial for the prevention, control, and management of infectious diseases. Nucleic acid testing represents a vital approach for the rapid diagnosis of pathogenic microorganism types. However, current nucleic acid detection methods face notable bottlenecks: traditional CRISPR fluorescence assays require time-consuming pre-amplification of target nucleic acids, while existing carbon-nanotube field-effect transistor (FET)-based platforms, though amplification-free, often necessitate complex chip surface modification and probe immobilization, and suffer from non-reusable chips, all limiting their utility in point-of-care testing (POCT) and large-scale screening. This study reports a CRISPR-based amplification-free RNA detection platform (CRISPR-FET) for the rapid identification of influenza A virus. The CRISPR-FET platform described herein enables the detection of viral RNA without amplification within 20 min, with a limit of detection as low as 1 copy/Î¼L. Secondly, a reporter RNA conjugated with gold particles is used to achieve signal amplification in FET detection; meanwhile, the method eliminates probe immobilization, thereby omitting this step and simplifying chip modification to reduce complex work-flows and pre-treatment costs. The chip's reusability further enhances cost-effectiveness. Additionally, streptavidin-modified magnetic bead adsorption minimizes background errors from excessive reporter RNA and non-target nucleic acids. Finally, validation with 24 clinical samples confirmed the platform's efficacy. By integrating rapidity, simplicity, and high sensitivity, alongside cost advantages from reusable chips, this CRISPR-FET platform meets the critical need for early influenza A diagnosis and holds promise for advancing POCT and large-scale epidemiological screening.",
    "disease": "influenza",
    "clean_text": "a crispr powered immobilization free amplification free carbon nanotube field effect transistor fet sensor for influenza a virus iav the epidemic of infectious diseases such as influenza a has imposed a severe health burden on the population early detection diagnosis reporting isolation and treatment are crucial for the prevention control and management of infectious diseases nucleic acid testing represents a vital approach for the rapid diagnosis of pathogenic microorganism types however current nucleic acid detection methods face notable bottlenecks traditional crispr fluorescence assays require time consuming pre amplification of target nucleic acids while existing carbon nanotube field effect transistor fet based platforms though amplification free often necessitate complex chip surface modification and probe immobilization and suffer from non reusable chips all limiting their utility in point of care testing poct and large scale screening this study reports a crispr based amplification free rna detection platform crispr fet for the rapid identification of influenza a virus the crispr fet platform described herein enables the detection of viral rna without amplification within min with a limit of detection as low as copy l secondly a reporter rna conjugated with gold particles is used to achieve signal amplification in fet detection meanwhile the method eliminates probe immobilization thereby omitting this step and simplifying chip modification to reduce complex work flows and pre treatment costs the chip s reusability further enhances cost effectiveness additionally streptavidin modified magnetic bead adsorption minimizes background errors from excessive reporter rna and non target nucleic acids finally validation with clinical samples confirmed the platform s efficacy by integrating rapidity simplicity and high sensitivity alongside cost advantages from reusable chips this crispr fet platform meets the critical need for early influenza a diagnosis and holds promise for advancing poct and large scale epidemiological screening"
}